# Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)

> **NCT02445053** · — · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 75 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** ivacaftor

## Key facts

- **NCT ID:** NCT02445053
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2020-10
- **Final completion:** 2020-10
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2020-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02445053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02445053, "Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02445053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*